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PPRECLINICAL STUDY
Effects of Oral Prednisone After Stenting
in a Rabbit Model of Established Atherosclerosis
Flavio Ribichini, MD,* Michael Joner, MD,‡ Valeria Ferrero, MD,* Aloke V. Finn, MD,†
Johanna Crimins, BA,† Gaku Nakazawa, MD,‡ Eduardo Acampado, DVM,‡
Frank D. Kolodgie, PHD,‡ Corrado Vassanelli, MD,* Renu Virmani, MD‡
Verona, Italy; Boston, Massachusetts; and Gaithersburg, Maryland
Objectives The aim of this study was to compare the effects of systemic prednisone in combination with a bare-metal stent
(BMS) or a paclitaxel-eluting stent (Taxus, Boston Scientific Corp., Natick, Massachusetts) on neointimal inhibi-
tion and vessel healing in an atherosclerotic rabbit model.
Background Inflammation plays a critical role in neointimal formation after coronary artery stenting. The efficacy of immuno-
suppressive doses of oral prednisone to inhibit in-stent neointimal proliferation was compared with BMS and
with a commercially available paclitaxel-eluting stent (Taxus) in a rabbit model of established atherosclerosis.
Methods Bilateral iliac artery injury in atherosclerotic New Zealand White rabbits fed an atherogenic diet was followed by
stent implantation. Animals randomly received Taxus stents, BMS (Express, Boston Scientific Corp.) and placebo,
or BMS and oral prednisone (2.1 mg/kg/day for the first 7 days, followed by 1.4 mg/kg/day for 14 days and 0.7
mg/kg/day for 21 days). Stented arterial segments were harvested at 42 days and processed for light micros-
copy, immunohistochemistry, and organoid culture.
Results Compared with control subjects, prednisone-treated animals showed a 30% reduction in percent stenosis (p 
0.009), a 35% decrease in neointimal area (p  0.003), and a 66% decrement in neointimal thickness (p 
0.001). Taxus stents also reduced all 3 parameters significantly (34%, 39%, and 83%, respectively), but
showed significantly more inflammatory cells and fibrin deposition and less endothelialization compared with
the other 2 groups. Plaque burden was equal among groups, as shown by the identical stent and vessel area,
and no remodeling was observed.
Conclusions Systemic prednisone treatment and Taxus stents reduce neointimal formation compared with BMS. The extent
of neointimal reduction is similar between prednisone- and Taxus stent-treated animals; however, Taxus stents
resulted in a significantly greater delay in healing. Targeting of inflammatory pathways after percutaneous
coronary intervention may be an efficacious way to prevent restenosis without the long-term risk of late
thrombosis. (J Am Coll Cardiol 2007;50:176–85) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.031p
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lhe local elution of cytostatic or cytotoxic drugs at vessel
all sites with drug-eluting stent (DES) technology has
emonstrated efficacy, but it is limited by long-term delay in
ealing and risks of late stent thrombosis, as well as
ypersensitivity reactions at the stented site (1,2). Targeting
ell proliferation in a nonspecific manner using either
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007, accepted March 6, 2007.aclitaxel or sirolimus significantly impairs many of the
ellular processes involved in arterial repair after injury.
Because inflammation is of cardinal importance among
he pathologic mechanisms of atherosclerosis and restenosis,
nterventions focused on reducing inflammatory signaling
ight attenuate restenosis without significantly delaying
rterial healing. Only recently, the use of the oral cortico-
teroid prednisone after bare-metal stent (BMS) deploy-
ent has yielded significant reductions in restenosis in
linical trials (3,4). In fact, steroids exert beneficial effects on
latelet function, smooth muscle cell proliferation, and
ollagen synthesis, as well as inflammatory cell migration
nd activation, thus interfering with several steps in the
ascade leading to neointima formation and subsequent
umen loss (5). It is possible that steroids might achieve
hese benefits without the same risks of delayed healing
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July 10, 2007:176–85 Prednisone After Stenting in Rabbit Modelnd late thrombosis seen with current-generation DES.
e therefore investigated the antirestenotic and anti-
nflammatory properties of steroids after BMS implantation
ersus the current generation Taxus stent in an atheroscle-
otic rabbit iliac model.
ethods
his protocol was approved by the Institutional Animal
are and Use Committee of the Armed Forces Institute of
athology and conformed to the position of the American
eart Association on use of animals in research.
abbit model of experimental atherosclerosis. The ex-
erimental preparation of the atherosclerotic animal model
s depicted in Figure 1. New Zealand White rabbits (3 to 4
g) 3 to 4 months of age were fed an atherogenic diet (1%
holesterol and 6% peanut oil, F4366-CHL, Bio-Serv, Inc.,
renchtown, New Jersey) for 5 weeks to induce atherosclerosis.
liac artery injury was induced 1 week following induction of a
igh-cholesterol diet using a Fogarty catheter (3-F) as de-
cribed previously (6). Following balloon injury, the animals
ere maintained on an atherogenic diet for 4 weeks. Subse-
uently the diet was switched to a low-cholesterol diet (con-
aining 0.025% cholesterol) until euthanasia.
lood analysis. Rabbits were phlebotomized and blood
ollected for the determination of total plasma cholesterol
Fig. 1). Serum C-reactive protein (CRP) measurements
ere performed using a highly sensitive 2-site enzyme-
inked immunoassay. Time points of detection were 24 h
nd 48 h after stenting, 4 weeks after stenting, and at
acrifice (42 days).
Figure 1 Experimental Study Layout
Time points of serum cholesterol measurements are highlighted (1  day 7, 2 tent placement and tissue har-
est. Premounted Express (con-
rol “bare” 316-L stainless-steel
tent 3  18 mm) or Taxus
tents (3  18 mm) (Boston
cientific Corp., Natick, Massa-
husetts) were implanted under
uoroscopic guidance. Stents
ere deployed bilaterally by in-
ation to their nominal pressures
or 30 s. Following stent deploy-
ent, angiography was per-
ormed to document stent placement and vessel patency.
All animals received aspirin 40 mg/day orally until eutha-
asia. In addition, heparin (150 IU/kg) was administered
ntra-arterially before catheterization procedures. Forty-two
ays after stenting, animals were anesthetized, and a before-
uthanasia angiogram of the iliac arteries was completed,
ollowed by euthanasia and perfusion-fixation. The stented
rteries were embedded in methylmethacrylate with sections
aken from the proximal, middle, and distal portions of the
tent. All sections were stained with H&E, Movat Penta-
hrome, and Carstair’s stains. To assess cellular proliferation,
nimals received bromodeoxyuridine (BrdU) before euthana-
ia, as previously described (6). Sections were also stained with
ntibodies to fibrin (American Diagnostica, Inc., Stamford,
onnecticut).
rug treatment. The animals were randomly allocated to 1
f 3 treatment groups: the first group received Express
etallic stents and served as the control group, the second
, 3  day 63, 4  day 84, and 5  day 105).
Abbreviations
and Acronyms
BMS  bare-metal stent
BSA  bovine serum
albumin
CRP  C-reactive protein
DES  drug-eluting stent
DMEM  Dulbecco’s
modified Eagle’s medium
LSM  low-serum mediaday 35
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Prednisone After Stenting in Rabbit Model July 10, 2007:176–85roup received Taxus stents (Taxus-treated group), and the
hird group received Express metallic stents followed by oral
dministration of prednisone (prednisone-treated group).
he administration of either placebo (groups 1 and 2) or
rednisone (group 3) was started the day of stenting,
aintained for 42 days, and administered as pills 3 times a
ay. The prednisone therapeutic scheme was as follows: 2.1
g/kg/day for the first 7 days, followed by 1.4 mg/kg/day
or 14 days and 0.7 mg/kg/day for 21 days.
rganoid culture. In selected animals from each treatment
roup (n  4 stents), stented arteries were explanted 7 days
ollowing deployment and perfused with ice-cold Ringer’s
actate at physiologic pressure (100 mm Hg). The specimens
ere harvested and immersed in fresh Dulbecco’s modified
agle’s medium (DMEM) containing 0.1% bovine serum
lbumin (BSA). Vessels were cut into stented and nonstented
ortions and put in serum-free media (DMEM 0.1% BSA,
ml/well) for 48 h. The supernatant (4 ml from 2 wells per
ample) was transferred into clean Eppendorf tubes, spun at
,500 rpm at room temperature for 15 min, and the superna-
ant was collected for analysis of cytokines using Cytokine
rray I (RayBiotech, Inc.). Each membrane contained 2
ndividual spots for each cytokine, as well as several positive
nd negative controls. Analysis was performed by densitometry
nd compared among treatment groups.
ell culture. Rabbit aortic smooth muscle cells were ob-
ained from the American Type Culture Collection (Manassas,
irginia) and maintained in rabbit aortic smooth muscle cell
rowth medium (Cell Applications, San Diego, California).
ollowing serum starvation in low-serum media (LSM)
DMEM  1% fetal calf serum), migration assays were
erformed in 24 well plates using Falcon HTS Fluoroblock
nserts (8-m pore size; Becton Dickinson Labware, Franklin
omparison of Morphometric Measurements Among Treatment Gro
Table 1 Comparison of Morphometric Measurements Among Tr
Measurements
BMS
(12 Stents)
Prednisone
(12 Stents)
EEL area (mm2) 7.78 1.41 7.50 0.98
Stent area (mm2) 6.54 1.01 6.02 0.73
Plaque area (mm2) 1.23 0.74 1.49 0.58
MS  bare-metal stent; EEL  external elastic lamina; NS  not specified.
omparison of Morphometric Measurements of the Neointima Amo
Table 2 Comparison of Morphometric Measurements of the Ne
Measurements
BMS
(12 Stents)
Prednisone
(12 Stents)
T
Neointimal area (mm2) 2.21 0.69 1.43 0.38 1
p Value
% stenosis 34 10 24 6
p Value
Intimal thickness (mm) 0.29 0.16 0.10 0.06 0
p Valuebbreviations as in Table 1.akes, New Jersey). The upper well was loaded with 350 l of
he cell suspension in LSMDMSO or LSM prednisone
100 M). The lower well contained 700 l of either LSM
MSO (control), LSM  100 ng/ml platelet-derived growth
actor (PDGF) (BB isoform; BioSource International, Cama-
illo, California)DMSO, or LSM PDGF prednisone.
he migrated cells were labeled by adding 1l Calcein-AM to
he lower well (1 mg/ml in dry dimethylsulfoxide, Molecular
robes, Eugene, Oregon). Pictures (100) were taken on an
nverted fluorescence microscope, and migrated cell fluores-
ence was quantified using Image J (7).
For investigation of cellular proliferation, rabbit aortic
mooth muscle cells were serum starved and media subse-
uently replaced with either LSM  DMSO, LSM  100
g/ml bFGF (Invitrogen Corp., Carlsbad, California), or
SM  100 ng/ml bFGF  prednisone (100 M). At 0,
4, and 48 h, pictures were taken and quantified as previ-
usly described (8).
The impact of prednisone (100 M; Sigma Aldrich, St.
ouis, Missouri) or paclitaxel (0.01M; Sigma Aldrich) on
e-endothelialization was assessed with a scratch assay using
uman umbilical vein endothelial cells as previously de-
cribed (9).
ata analysis. All arterial segments were examined with
he observer blinded to the treatment group. Stents were
valuated for thrombus formation, inflammation, and cellular
roliferation. Computerized planimetry was performed (IP
ab, Vienna, Virginia) on all stented sections as previously
escribed (6). The neointimal cell proliferation index (percent
roliferating cells) was defined as the ratio of BrdU-positive
eointimal cells to total neointimal cell number.
Fibrin was identified on H&E and Carstair’s stained
ections and semiquantified as previously described (6,10).
2 Days After Stent Implantation
ent Groups 42 Days After Stent Implantation
Stent
tents)
p Value
Prednisone
vs. BMS
Taxus
vs. BMS
Taxus
vs. Prednisone
0.91 NS NS NS
0.66 NS NS NS
0.48 NS NS NS
eatment Groups 42 Days After Stent Implantation
a Among Treatment Groups 42 Days After Stent Implantation
tent
nts)
% Reduction and p Value
Prednisone
vs. BMS
Taxus
vs. BMS
Taxus
vs. Prednisone
0.28 35% 39% 6%
0.003 0.003 NS
4 30% 34% 5%
0.009 0.006 NS
0.05 66% 83% 50%
0.001 0.0006 0.02ups 4
eatm
Taxus
(9 S
7.13
6.00
1.13ng Tr
ointim
axus S
(9 Ste
.34
23
.05
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July 10, 2007:176–85 Prednisone After Stenting in Rabbit Modelntifibrin stain was quantified as a percentage of neointimal
ositive area ([total neointimal positive area/ neointima
rea] · 100).
Cytokine quantification was performed by densitome-
ry using Gel-Pro-Analyser software (Version 4.5 for
indows, Media Cybernetics). Values for each cytokine
ere derived by extrapolation to a standard curve and
Figure 2 Histologic Sections of the Iliac Arteries 42 Days After
(A to C) Sections show low-power (20, top) and high-power (100/200, bottom
greater in the control group (A) as compared with prednisone-treated animals (B)
control group and prednisone-treated rabbits (30%) and Taxus stents (34%).
omparison of Histologic Findings Among Treatment Groups 42 Da
Table 3 Comparison of Histologic Findings Among Treatment G
Measurements
BMS
(12 Stents)
Prednisone
(12 Stents)
Fibrin score 1.2 (0.9–1.4) 0.8 (0.7–1.0)
% Neointimal fibrin 0.4 0.3 1.3 1.2
% Endothelialization 83 9 84 10Ordinal data are presented as median and interquartile range and analyzed by the Wilcoxon rank-sum t
Abbreviations as in Table 1.ormalization to the density of a provided negative
ontrol. Corresponding values from individual cytokines
ere compared among groups within proximal, stented,
nd distal sections.
tatistical analysis. Numerical data are presented as mean
SD. Continuous variables were first checked for normal
istribution by the Shapiro-Wilk goodness-of-fit test and
t Implantation and Bar Graph of Percent Stenosis
nification following Movat Pentachrome staining. Percent stent stenosis is much
xus stents (C). (D) The bar graph shows a significant reduction between the
ter Stent Implantation
s 42 Days After Stent Implantation
s Stent
Stents)
p Value
Prednisone
vs. BMS
Taxus
vs. BMS
Taxus
vs. Prednisone
1.5–2.0) NS* 0.004* 0.008*
 3.6 NS 0.03 0.05
 15 NS 0.004 0.002Sten
) mag
and Tays Af
roup
Taxu
(9
1.7 (
5.0
64est.
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Prednisone After Stenting in Rabbit Model July 10, 2007:176–85nalysis of variance or by the Wilcoxon rank-sum test
erformed where suitable. Dunnett’s or Bonferroni post-
oc adjustment was used to determine significant differ-
nces, and a p value 0.05 (p  0.016 after Bonferroni
orrection for multiple, i.e., triple comparisons) was consid-
red statistically significant. Ordinal data were analyzed by
he Wilcoxon rank-sum test.
esults
wenty-two animals formed the histomorphometric
tudy, and 6 animals were used for the organoid culture.
ne animal from the prednisone group died during
mplantation because of procedural complications. An-
ther animal from the Express control group was eutha-
ized because of unacceptably high weight loss, lethargy,
Figure 3 Fibrin Presence in the Iliac Arteries 42 Days After Ste
Photomicrographs showing fibrin deposition around stent struts using Carstair’s st
hematoxylin-eosin (G to I) in control animals (A, D, G), prednisone-treated animals
stents after 42 days. (J) Bar graph showing significantly greater percentage of fibrnd icterus. Two rabbits from the Taxus stent group and
control rabbit were found dead 1 day following stent
mplantation. In all 3 animals, postmortem revealed iliac
rterial dissections, likely secondary to stent implanta-
ion. All other animals appeared healthy, without weight
oss for the duration of the protocol. Seventeen animals
urvived until scheduled euthanasia (6 prednisone, 5
axus, and 6 control animals).
Analysis of blood cholesterol levels revealed similar base-
ine parameters among treatment groups, with a mean
erum-cholesterol of 640  406 mg/dl for control, 991 
36 mg/dl for prednisone and 574  365 mg/dl for Taxus
tent rabbits (p  NS) at the time point of stent implan-
ation (day 63). No significant differences were observed at
acrifice (data not shown). Serum CRP was significantly
plantation and Bar Graph for Percentage of Fibrin Area
to C) (pink color), stain with antibody against fibrin (D to F) (brown color) and
, H) and Taxus stents (C, F, I). Note that maximum fibrin is seen in Taxus
in Taxus stents compared with control or prednisone-treated animals.nt Im
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(B, E
in area
r
c
t
v
n
s
h
a
H
1
(
r
t
g
a
w
(
s
s
a
T
c
(
F
r
i
b
n
(
n
p
i
o
C
B
181JACC Vol. 50, No. 2, 2007 Ribichini et al.
July 10, 2007:176–85 Prednisone After Stenting in Rabbit Modeleduced in prednisone-treated rabbits 24 h after stenting
ompared with Taxus stent-treated rabbits and was similar
o control rabbits at this time point (73.37  12.35 ng/ml
s. 106.81  5.56 ng/ml, p  0.04 and 80.46  21.39
g/ml [control], p  NS). The CRP levels remained
ignificantly lower in prednisone-treated rabbits at 48 h;
owever, no significant differences were observed at 4 weeks
nd at the time point of sacrifice (day 105).
istomorphometry. Histomorphometry was performed in
2 Express stents deployed in 6 placebo-treated rabbits
control group), 12 stents deployed in 6 prednisone-treated
abbits, and 9 Taxus stents deployed in 5 rabbits (1 stent was
otally occluded and excluded from analysis).
The experimental baseline conditions created in the 3
roups were identical in terms of external elastic lamina
rea, stent area, and plaque area (Table 1). Arterial injury
as mild in all treatment groups (mean injury score 1)
data not shown).
Figure 4 Inflammation at Luminal Surfaces and Bar Graph for t
Demonstration of luminal eosinophils/heterophils after staining with H&E at high (
erophils are seen in Taxus stents (C) versus prednisone-treated (B) and control (A
cells among treatment groups.
omparison of Proliferation Index and Luminal Eosinophils/Heterop
Table 4 Comparison of Proliferation Index and Luminal Eosinop
Measurements
BMS
(12 Stents)
Prednisone
(12 Stents)
Mean BrdU index 0.08 0.05 0.10 0.04
Mean no. of eosinophils/heterophils 32 24 27 20
rdU  bromodeoxyuridine; other abbreviations as in Table 1.Oral immunosuppression with prednisone resulted in a
ignificant reduction in neointimal area, thickness between
truts, and percent stent stenosis compared with control
nimals (35%, 66%, and 30% reduction, respectively).
axus stents also showed highly significant differences
ompared with control animals in terms of these end points
39%, 83%, and 34% reduction, respectively) (Table 2,
ig. 2). Taxus stent deployment resulted in statistically similar
esults compared with prednisone treatment when we exam-
ned reduction in neointimal area and percent stent stenosis,
ut was superior in terms of suppression of neointimal thick-
ess (50% reduction compared to prednisone, p  0.02)
Table 2). There was almost complete endothelialization and
eointimal coverage around stent struts in control and
rednisone-treated animals, whereas Taxus stent-treated arter-
es showed incomplete healing, characterized by large amounts
f fibrin deposition and uncovered stent struts.
terophils/Eosinophils
, insets at 400) magnification. Note, greatest number of eosinophils/het-
als. (D) Bar graph demonstrating significant differences in luminal inflammatory
mong Treatment Groups
Heterophils Among Treatment Groups
Taxus Stent
(9 Stents)
p Value
Prednisone
vs. BMS
Taxus
vs. BMS
Taxus
vs. Prednisone
0.05 0.03 NS NS 0.005
72 33 NS 0.01 0.001he He
200
) animhils A
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Prednisone After Stenting in Rabbit Model July 10, 2007:176–85The fibrin score was significantly higher in the Taxus
tent group compared with control subjects (1.7 [inter-
uartile range (IQR) 1.5 to 2.0] vs. 1.2 [IQR 0.9 to 1.4],
 0.003) and this difference was even more pronounced
hen compared with prednisone treated animals (1.7
IQR 1.5 to 2.0] vs. 0.8 [IQR 0.7 to 1.0], p  0.008)
Table 3). Following immunostaining for fibrin, Taxus
tents showed significantly greater fibrin deposition com-
ared with prednisone-treated and control rabbits (Taxus
s. control 5.0  3.6% vs. 0.4  0.3%, p  0.03;
rednisone-treated vs. control 1.3  1.2% vs. 0.4  0.3%,
 NS; and Taxus vs. prednisone-treated 5.0  3.6% vs.
.3  1.2%, p  0.05) (Fig. 3).
Inflammatory cells consisted mainly of macrophages and
ymphocytes with minor giant cell reaction, which were
qually observed in all three groups. However, in Taxus
tents, the mean number of eosinophils/heterophils toward
he lumen was significantly greater compared with control
nd prednisone-treated animals (Taxus 72  33 vs. control
nimals 32  24, p  0.01 and prednisone 27  20, p 
.001) (Table 4, Fig. 4).
Neointimal cell proliferation was lowest in Taxus stents and
as significantly less compared with prednisone-treated rabbits
p  0.005), whereas no significant difference was observed
etween prednisone-treated and control rabbits (Table 4).
ytokine array of organoid cultures. Cultured stented
rteries predominantly produced immunogenic and chemoat-
ractant cytokines such as interleukins and growth factors at 7
ays. Most of these released cytokines, detected by individual
Figure 5 Bar Graphs of Inflammatory Cytokine Release
Bar graphs representing changes in inflammatory cytokine release among control a
quantification of individual cytokines was performed by densitometry analysis and
control arteries by analysis of variance with Bonferroni correction (p  0.25). Pred
protein (MCP)-2 (p  0.002), MCP-3 (p  0.009), and tumor necrosis factor (TNF)
led to a further significant reduction of interleukin (IL)-10 (p  0.01), IL-13 (p  0
nificance between Taxus and bare-metal stents; significance between prednisonepots on X-ray films, showed similar response patterns among
he 3 treatment groups, demonstrating reduced release in both
he prednisone and Taxus as compared with control arteries.
ignificant decrease among prednisone or Taxus compared with
ontrol arteries was observed for interleukin-6, -10, and -13;
onocyte chemoattractant protein-1, -2, and -3; regulated on
ctivation, normal T cell expressed and secreted; transforming
rowth factor-beta; and tumor necrosis factor-alpha (Fig. 5).
ellular proliferation and migration in vitro. Rabbit
ortic SMCs treated with prednisone demonstrated signif-
cantly diminished migration (1.67  0.45-fold, p  0.03)
ompared with untreated but stimulated (PDGF) cells (2.92
0.38-fold). There was no difference in proliferation
etween cells treated with bFGF alone and bFGF and
rednisone.
e-endothelialization in vitro. Re-endothelialization fol-
owing scratch injury was significantly delayed in paclitaxel-
reated endothelial cells compared with control cells (p 
.02). This delay was even more pronounced when com-
ared with prednisone-treated endothelial cells (p 0.003).
ost important, there was no delay in re-endothelialization
n prednisone-treated cells compared with control cells
p  NS) (Fig. 6).
iscussion
his study demonstrates that, in the experimental model
f atherosclerotic rabbits, oral administration of pred-
isone causes a significant 30% reduction in percent stent
tenosis and allows for complete re-endothelialization
dnisone- and Taxus-treated arteries 7 days following stent implantation. Semi-
sed as pixels. Differences were considered significant following comparison with
reduced the release of interleukin (IL)-6 (p  0.02), monocyte chemoattractant
(p  0.01) significantly compared with control subjects, whereas Taxus stents
MCP-1 (p  0.007), and transforming growth factor (TGF)-beta (p  0.01). *Sig-
are-metal stent. GRO-a  growth-related oncoprotein-alpha.nd pre
expres
nisone
-alpha
.003),
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July 10, 2007:176–85 Prednisone After Stenting in Rabbit Modelfter implantation of BMS. In vitro findings with endo-
helial cells confirmed that prednisone does not interfere
ith re-endothelialization following scratch injury at
elatively high concentrations. Although the Taxus stent
aused greater neointimal inhibition, it also resulted in
istologic evidence of incomplete healing characterized
y persistent fibrin deposition, inflammation, and incom-
lete endothelialization in vivo and in vitro.
The concept that systemic administration of immunosup-
ressant agents such as prednisone may reduce neointimal
ormation after coronary stent placement without impeding
rterial healing is an important one. Although current-
Figure 6 In Vitro Scratch Assay With Human Umbilical Vein En
Representative photomicrographs of scratch injury following treatment with either l
LSECM  prednisone (B), or LSECM  paclitaxel (C) (0.01 M). Graphic analysis
cell density increase values for the control and prednisone treatment conditions (D
dition (53.68 cells/area  12.29) compared with both the control (209.89  32.eneration DES are effective in reducing rates of target vessel wevascularization, they do so at the cost of inhibition of arterial
ealing, which requires long-term dual antiplatelet therapy to
educe the risks of thrombosis. Multiple studies have con-
rmed that the most important risk factor for late stent
hrombosis after DES placement is withdrawal of antiplatelet
herapy. We recently reported (11) a long-term delay of arterial
ealing after DES implantation in humans, characterized by
brin deposition, inflammation, and poor endothelialization as
he pathologic substrate underlying late stent thrombosis.
he experimental animal model. Unlike prior experimen-
al studies performed with the commercially available DES,
ur investigation was performed in atherosclerotic animals,
lial Cells and the Bar Graph of Cell Density
rum essential culture media (LSECM)  dimethyl sulphoxide (control) (A),
atch assay indicates that there is no significant difference between endothelial
re is a significantly less increase in cell density in the paclitaxel treatment con-
d the prednisone (260.16  51.40) treatment conditions.dothe
ow se
of scr
). The
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Prednisone After Stenting in Rabbit Model July 10, 2007:176–85ercutaneous interventions in preclinical studies (1,2). In
he specific setting of DES implantation, there are concerns
hat the extraordinary efficacy observed in the short term in
ealthy animals (and supported by initial clinical experience
n humans) may not be sustained in the long term (12). In
ur study, prednisone-treated animals received tapered
oses of steroids to reproduce human protocols and to
inimize possible undesirable effects, and the histomorpho-
etric analyses were obtained at midterm (42 days) rather
han at 28 days.
Moreover, the development of an atherosclerotic plaque
efore stenting ensures a more aggressive neointimal response
ith an important inflammatory reaction compared with
ealthy animal models. The efficacy of prednisone observed in
ur experiment is most likely related to its anti-inflammatory
roperties, whereas Taxus stents coated with an antiprolifera-
ive drug have undesirable effects resulting in persistent fibrin
eposition, poor endothelialization, and induction of an eosin-
philic/heterophilic inflammatory response.
ntirestenotic mechanisms of glucocorticoids. Glu-
ocorticoids are well known to suppress several inflamma-
ory pathways by interacting with NF-kappa B, thus block-
ng its transcriptional activity (13,14). The reduced
ranscription of various proinflammatory genes results in
iminished release of inflammatory cytokines, chemokines,
nd cell adhesion molecules. Our study confirmed a mark-
dly reduced release of inflammatory cytokines in stented
rteries 7 days following prednisone treatment, which likely
ontributed to the beneficial effect on neointimal growth
bserved at midterm follow-up (42 days). In contrast,
aclitaxel is known to interrupt mitosis by promoting and
tabilizing microtuble formation and, therefore, acts as an
ntiproliferative drug, with minor effects on arterial inflam-
ation. The diminished release of inflammatory cytokines
btained at 7 days with Taxus stents in our study might
herefore be explained by toxic effects on vascular cells,
esulting in decreased cellular viability rather than suppres-
ion of the inflammatory reaction. The histologic response
t 42 days, however, suggests a catch-up phenomenon of
eointimal inflammation, as demonstrated by sustained
brin deposition and eosinophilic/heterophilic infiltration.
The antiproliferative effects of glucocorticoids are well
haracterized, and there is consensus that persisting high
evels are necessary to efficiently inhibit proliferation of
ascular smooth muscle cells (15). In the current study,
n vitro experiments revealed an absence of antiproliferative
ffects at concentrations comparable to those used in vivo.
owever, there was a clear effect on migration of SMCs,
hich might occur independent of antiproliferative effects at
elevant concentrations. Most important, re-endothelialization
as not delayed in vitro using the same concentrations of
rednisone that were shown effective in suppressing migration
f SMCs. Further investigation is needed to determine the
ifferential response of vascular SMC and endothelial cells to
rednisone treatment. somparison with other preclinical studies. A previous
nimal study (16) reported a significant decrease of inflamma-
ion following implantation of dexamethasone-eluting stents in
ig coronary arteries at 5 days. However, no beneficial effect on
eointimal growth was observed at 28 days, which reinforces
he need for appropriate animal models and drug dosage to
imulate human atherosclerotic disease.
Furthermore, the local or systemic administration is of
ardinal importance to determine the efficacy of glucocor-
icoids with respect to their antirestenotic properties. In
ontrast to corticosteroids, preclinical models using pacli-
axel have shown effective suppression of neointima at short
erm. In a previous experimental model of healthy rabbits
mplanted with stents loaded with a lower dose of paclitaxel
42.0 g), neointimal thickness was reduced by 48% com-
ared to BMS at 28 days (12). However, as in our study,
aclitaxel-DES were associated with significantly larger
reas of fibrin deposition surrounding stent struts and sparse
overage of neointima with signs of incomplete healing.
hese morphologic findings suggest local toxic effects of
aclitaxel, which were no longer apparent at 90 days, and
eointimal thickness was similar to control BMS (12). In a
ecently published investigation, high-dose paclitaxel-
oaded stents (1.44 g/mm2) implanted in healthy pigs
onfirmed a 50% reduction of neointima compared with
ontrol subjects at 28 days, but also a total loss of the
nhibitory effect on the neointima at 90 days (17).
In the present experiment, the commercially available
axus stent, loaded with 1.0 g/mm2 of paclitaxel, reduced
ercentage of stent stenosis very effectively (34%) at 42
ays in the setting of an underlying atherosclerotic plaque
urden, confirming the efficacy of the Taxus stent at the
idterm. As in previously mentioned studies, the Taxus
tent was associated with significantly larger areas of fibrin
eposition (Fig. 3), inflammatory cells surrounding stent
truts, and sparse coverage of neointima by endothelial cells,
esulting in incomplete healing.
omparison with clinical studies. Quantitative coronary
nalysis of patients with implanted Taxus stents in clinical
rials have demonstrated a late loss to vary between 0.36 
.48 mm and 0.39  0.50 mm at 6 to 9 months compared
ith approximately 0.92  0.58 mm in BMS control
atients (18,19). In-stent late loss observed in BMS and oral
rednisone in the IMPRESS studies varied from 0.39 
.06 mm to 0.61  0.35 mm at 6 to 8 months compared
ith 0.85 0.6 mm in control patients (3,4). These angio-
raphic results seem to encompass the morphologic obser-
ations described in our animal study and may be sufficient
o avoid clinical recurrence. In fact, it is now accepted that
n-stent late-loss values 0.75 mm practically avoid the
azard of clinical restenosis and that further reductions of
ate loss may be clinically meaningless (20).
The drawback to this approach is its limited applicability.
nly 15% of patients in the former study fulfilled enroll-
ent criteria. In the real world, the well-known unfavorableide effects of oral prednisone, such as hypertension, im-
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July 10, 2007:176–85 Prednisone After Stenting in Rabbit Modelaired glucose tolerance, immunosuppression, impaired
ealing after myocardial infarction, and increased risk for
astric ulcers would preclude its use in some patients
oming to the catheterization laboratory because of the high
ncidence of comorbid conditions, such as diabetes or
ongestive heart failure, that would only be exacerbated by
teroid therapy. On the other hand, there are also important
enefits to oral prednisone not provided by other ap-
roaches, such as DES, and these include low cost of
reatment and lack of long-term need for dual antiplatelet
herapy after percutaneous coronary intervention. These
dvantages, especially the latter, should not be understated,
specially because the optimal duration of antiplatelet ther-
py after DES is yet to be determined.
tudy limitations. Our study does not address possible
ifferences between mid- and long-term results of the
fficacy of oral prednisone. However, on the basis of the
elatively favorable histologic findings observed with oral
rednisone (complete healing, absence of fibrin deposits,
nd less inflammation compared with the paclitaxel DES),
t seems unlikely that the long-term result of this strategy
ould be worse than those reported here. However, further
esearch is warranted to address this issue.
onclusions
ral administration of immunosuppressive dose of pred-
isone for 42 days following BMS implantation in athero-
clerotic animals, as used in clinical studies, results in a
ignificant reduction in percent stent stenosis (i.e., neointi-
al growth) compared with BMS. The magnitude of the
ntirestenotic effect of prednisone observed in this experi-
ental model is similar to that obtained with Taxus stents,
ut with a more favorable healing aspect. These findings
upport the encouraging clinical and angiographic findings
eported in preliminary clinical studies. However, in making
linical decisions about whether to use adjunctive steroid
herapy after percutaneous coronary intervention, one must
eigh the well-known adverse side effects of oral prednisone
herapy against its potential benefits as an antirestenotic
gent that does not appear to delay healing (at least in
reclinical models).
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